Delcath Systems (NASDAQ:DCTH) Releases Earnings Results, Beats Expectations By $0.16 EPS

Delcath Systems (NASDAQ:DCTH) issued its earnings results on Thursday. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16, FiscalAI reports. The business had revenue of $29.13 million during the quarter, compared to analysts’ expectations of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.47%.

Here are the key takeaways from Delcath Systems’ conference call:

• HEPZATO revenue and guidance increased: Second-quarter HEPZATO KIT revenue reached $27.1 million, up 21% year over year, while volume rose 30% despite the impact of 340B pricing. Delcath raised full-year 2026 revenue guidance to $104 million-$108 million and expects positive adjusted EBITDA.
• Commercial footprint continued to expand: The company activated two treatment centers in the quarter, reaching 31, and remains confident it can reach approximately 37 centers by year-end. New patient starts averaged about 0.5 per site per month, with leading NCI- and NCCN-affiliated institutions making up a substantial portion of the network.
• Expansion into additional cancers is progressing but remains early: Phase II studies in third-line liver-dominant colorectal cancer and HER2-negative metastatic breast cancer are adding sites and improving enrollment, while an interim colorectal readout is expected in late 2027. Management acknowledged that enrollment has been slower than initially expected because of the complexity of coordinating oncology and interventional radiology teams.
• Profitability was supported by strong gross margins, but investment and pricing pressures remain: Second-quarter gross margin improved to 90%, although full-year guidance is 86%-89% due partly to anticipated manufacturing costs. Research and development and selling, general and administrative expenses increased year over year, while adjusted EBITDA declined to $7.6 million from $9.8 million.

Delcath Systems Stock Performance

Shares of NASDAQ DCTH traded down $0.36 during trading on Friday, hitting $15.11. 1,212,338 shares of the company were exchanged, compared to its average volume of 498,787. The company has a fifty day moving average price of $12.35 and a 200-day moving average price of $10.87. The firm has a market capitalization of $521.60 million, a PE ratio of 1,512.51 and a beta of 0.52. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $16.38.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd raised its stake in Delcath Systems by 339.4% during the fourth quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock worth $719,000 after purchasing an additional 54,990 shares during the period. Millennium Management LLC boosted its holdings in Delcath Systems by 3.0% in the 4th quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock valued at $2,489,000 after purchasing an additional 7,190 shares during the last quarter. Man Group plc grew its stake in shares of Delcath Systems by 34.1% in the 4th quarter. Man Group plc now owns 38,158 shares of the company’s stock valued at $385,000 after buying an additional 9,705 shares during the period. Balyasny Asset Management L.P. grew its stake in shares of Delcath Systems by 69.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock valued at $527,000 after buying an additional 21,384 shares during the period. Finally, Jump Financial LLC increased its holdings in shares of Delcath Systems by 68.0% during the 4th quarter. Jump Financial LLC now owns 45,953 shares of the company’s stock worth $464,000 after buying an additional 18,596 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems News Roundup

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research note on Friday. Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. BTIG Research raised their target price on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.17.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.